BCPC
Balchem Corporation157.10
-1.61-1.01%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Marketing pilots deliver ROI, science advances
Q&A revealed strong ROI from Jets partnership, shifting VitaCholine focus to adult cognition and sparking energy drink SKUs, while Bayern Munich boosts K2VITAL in women's health—prompting plans for MSM beauty-from-within campaigns and more digital marketing. Europe A&H shows early volume/price gains post-antidumping duties, aided by a key country-of-origin ruling. Tariffs pose manageable volatility after mitigations cut impact to $10M. Management guides 23% tax rate, flags minor FX tailwinds, and prioritizes organic growth/M&A amid low leverage enabling buybacks. No major shifts; Q&A reaffirms momentum. Sports bets paid off big.
Key Stats
Market Cap
5.10BP/E (TTM)
34.38Basic EPS (TTM)
4.57Dividend Yield
0.01%Recent Filings
8-K
Record Q4 sales, earnings growth
Balchem reported Q4 net sales of $263.6 million, up 9.8%, and net earnings of $39.2 million, up 16.8%, with growth across all segments fueled by nutrition platforms. Full-year sales hit a record $1.037 billion, up 8.8%, alongside record adjusted EBITDA of $274.9 million. Growth persists. Net debt sits low at $89.4 million.
10-K
FY2025 results
Balchem drove FY2025 net sales to $1.04B, up 8.8% y/y, with HNH surging 9.9% on nutrients and food ingredients, ANH climbing 7.5% via pricing in ruminants and monogastrics, and SP edging 6.2% higher; operating margin expanded to 20.2% from 19.2% despite input cost pressures, fueled by volume/mix and favorable pricing. Q4 sales hit $264M while gross margins held firm, capping a year of steady quarterly acceleration across segments. Cash from operations swelled 19% to $217M, funding $43M capex, $108M buybacks under a fresh 4M-share program, and a $0.96/share dividend. Strong liquidity persists with $74M cash and $386M revolver capacity. EtO regulatory scrutiny threatens SP momentum.
8-K
Gilson succeeds retiring CAO
Balchem Corporation named Erin L. Gilson as Vice President and Chief Accounting Officer effective April 1, 2026, succeeding retiring William A. Backus on March 31. Gilson, a company veteran since 2016 as Senior Director of Accounting and Financial Reporting, steps up seamlessly. No changes to her compensation. Smooth internal transition preserves accounting continuity.
8-K
Dividend hiked 10.3%; 4M share buyback
Balchem declared a $0.96 per share dividend on December 9, 2025, payable January 20, 2026 to holders of record December 23—up 10.3% from last year, marking the 17th straight hike. Board also greenlit a new repurchase program for up to 4 million shares, with no expiration. Signals board confidence. Yet risks lurk in forward-looking statements.
8-K
Record Q3 sales, earnings up
Balchem posted record Q3 net sales of $267.6 million, up 11.5%, with net earnings of $40.3 million rising 19.1% and adjusted EBITDA of $71.4 million climbing 11.0%. All three segments grew, fueled by specialty nutrients and 'better for you' trends, yet higher input costs bit margins. Growth spans every segment. Secured approvals for a new NY microencapsulation plant to double capacity; repaid $36 million debt.
IPO
Website
Employees
Sector
Industry
ALB
Albemarle Corporation
131.07-1.15
ASH
Ashland Inc.
58.65-1.18
BGLC
BioNexus Gene Lab Corp
4.12-0.02
BON
Bon Natural Life Limited
1.79+0.04
CC
Chemours Company (The)
11.69-0.09
HUN
Huntsman Corporation
9.90-0.51
IFF
International Flavors & Fragran
64.58+0.41
IOSP
Innospec Inc.
77.99-0.39
NTIC
Northern Technologies Internati
7.81+0.25
SQM
Sociedad Quimica y Minera S.A.
64.17-0.80